Knight Therapeutics

L'entreprise

Knight Therapeutics acquires, in-licenses and distributes branded pharmaceutical products across Canada and Latin America, focused on specialty and branded generics.

It has historically carried a large cash balance as optionality for deals, and is now converting that into a growing operating business.

Les avantages concurrentiels

A built-out pan-Latin-American commercial and regulatory distribution platform is hard to replicate and gives partners a single route to the region.

A strong, largely net-cash balance sheet provides deal-making optionality.

Aperçu financier

Période déclarée la plus récente : Q1 FY2026 (ended March 31, 2026). Les chiffres reflètent la date de révision — confirmez les chiffres actuels avant d'agir.

Rendement du flux de trésorerie disponible et croissance durable

Rendement du flux de trésorerie disponible : ≈4% (est.)adj. EBITDA ≈15% of ~C$515M revenue vs ~C$0.96B market cap

For a growing specialty-pharma platform, watch the trajectory of EBITDA-to-cash conversion alongside the net-cash balance sheet — Knight is early in turning strong EBITDA growth into consistent free cash flow.

The roughly C$127M of cash and securities (net cash ≈C$69M) is both a margin of safety and dry powder for the tuck-in acquisitions that drive the model.

Sustainable growth: fueled by product launches and acquisitions across Latin America; trailing revenue is up ~39%, with FY2026 guidance raised — durable if the deal pipeline and launches continue.

Voir le classement complet du rendement du flux de trésorerie disponible →

Valorisation et points à surveiller

Knight has often traded near its book value, treated by the market as a 'cash-plus-optionality' story rather than an operating compounder.

That framing is being tested as revenue (+68% in Q1) and EBITDA (+130%) scale — the question is whether the market re-rates it as a genuine growth platform.

Dividende

Not an income stock — Knight retains capital for acquisitions and buybacks rather than paying a meaningful dividend.

Risques et scénario baissier

• Latin American currency and macro volatility.
• Product and supplier concentration; launch timing.
• Capital-allocation track record is scrutinized given the historical cash pile.
• Integration and regulatory risk across multiple jurisdictions.

Faits récents

Q1 FY2026 revenue topped C$148M (+68%) with adjusted EBITDA of C$28M (+130%); Knight raised FY2026 revenue guidance to C$510–525M while holding ≈C$127M in cash and securities.

Verdict

A cash-backed specialty-pharma platform finally showing real operating growth. The bull case is a re-rating from 'cash story' to 'growth platform' as EBITDA scales; the bear case is Latin American volatility and lumpy deal-driven results. Conviction: growth-plus-optionality idea for investors comfortable with EM exposure.